MET and familial pancreatic carcinoma: As a result, SHR-A1403 demonstrated strong preclinical anti-tumor efficacy in pancreatic cancer, indicating its potential use as a c-MET-targeted antibody-drug conjugate treatment for PDAC in clinical practice (104).